Evotec SE Stock

Price

Target price

/ Tradegate WKN: 566480 / Name: Evotec / Stock / Biotechnology & Medical Research / Mid Cap /

Latest predictions

buy

Your prediction

Evotec SE Stock

Evotec SE dominated the market today, gaining €0.20 (3.380%).

With 10 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.

With a target price of 48 € there is potential for a 680.49% increase which would mean more than doubling the current price of 6.15 € for Evotec SE.

So far the community has only identified positive things for Evotec SE stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Evotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.

Feedback

Pros and Cons of Evotec SE in the next few years

Pros

W********* I********* f** t** n*** y****

C******** o* t** e**********

M***** P*******

Cons

B****

S********** s********

G***** c******* t* c**********

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

Performance of Evotec SE vs. its peers

Security	Change(%)	1w	1m	1y	YTD	3y	5y
Evotec SE
Ironwood Pharmaceuticals
Arrowhead Pharmaceuticals Inc.
Novocure Ltd

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

Last updated at 2024-08-01

Evaluating the financials of Evotec, a prominent player in the biotechnology and medical research industry, reveals a complex picture. On one hand, the company has shown strong revenue growth and possesses significant assets, pointing towards potential for future success. On the other hand, persistent losses in net income and an elevated level of operating expenses present challenges that cannot be ignored. Analyzing these aspects can provide valuable insights into Evotec's current financial health and its standing within the competitive landscape.

Strong Revenue Growth: Over the last few years, Evotec has displayed a notable growth trajectory in revenue. The total revenue for 2023 was recorded at approximately €781 million, which indicates solid demand for its services and products. The revenue per share also stands at €4.39, showcasing its capability to generate income efficiently.

Market Capitalization: With a market capitalization of approximately €1.56 billion, Evotec demonstrates solid investor confidence in its business model and long-term potential within the biotechnology sector. This can be an indicator of positive market sentiment.

Feedback